artivion.com Open in urlscan Pro
35.199.179.76  Public Scan

Form analysis
1 forms found in the DOM

https://artivion.com

<form action="https://artivion.com">
  <input name="s" class="h-10" type="text">
  <button type="submit" class="icon icon-search"></button>
</form>

Text Content

 * News
 * Events
 * Contact

 * 

 * About
 * Products
 * Education


 * Donor Services
 * Quality & Safety
 * Investors
 * Careers


 * About
 * Products
 * Education

 * Donor Services
 * Quality & Safety
 * Investors
 * Careers




ADVANCING AORTIC TECHNOLOGIES
WITH PURPOSE™

‹›

‹›

Our purpose is to develop simple, elegant solutions that address cardiac and
vascular surgeons’ most difficult challenges in treating patients with diseases
of the aorta and to deliver breakthrough technologies of unsurpassed quality
that have far-reaching impact.
Meet Artivion

July 27, 2022


ARTIVION INITIATES ENROLLMENT IN PERSEVERE CLINICAL TRIAL



Study Designed to Evaluate the Safety and Efficacy of the AMDS Hybrid Prosthesis
to Treat Acute DeBakey Type I Aortic Dissections & Support U.S. FDA PMA
Submission.




FDA ACCEPTS CRYOLIFE IDE APPLICATION FOR PERSEVERE PIVOTAL IDE STUDY



A Prospective, Single Arm, Multi-center Clinical Investigation, to Evaluate the
Saftey and Effectiveness of AMDSTM  in the Treatment of Acute DeBakey Type I
Dissection



July 29, 2021


CRYOLIFE ANNOUNCES SALE OF PERCLOT TO BAXTER



CryoLife Announces the Sale of PerClot to a subsidiary of Baxter International,
Inc.



September 2, 2020


CRYOLIFE ACQUIRES ASCYRUS MEDICAL



CryoLife Acquires Ascyrus Medical LLC, Developer of AMDS Hybrid Prosthesis.
Ascyrus is a Florida-based, privately-held developer of the Ascyrus Medical
Dissection Stent (AMDS™), the world’s first aortic arch remodeling device used
for the treatment of acute Type A aortic dissections.



January 29, 2024


ARTIVION ANNOUNCES PRESENTATION OF LATE-BREAKING DATA FROM AMDS PERSEVERE TRIAL
AT THE 60TH SOCIETY OF THORACIC SURGERY ANNUAL MEETING



Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause
Mortality and Primary Major Adverse Events (MAEs) at 30 days with use of AMDS in
Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion



November 9, 2023


ARTIVION ANNOUNCES COMPLETION OF ENROLLMENT IN PERSEVERE TRIAL.



The PERSEVERE trial is a prospective, multicenter, non-randomized clinical trial
to determine if patients with acute DeBakey Type I aortic dissection can be
treated safely and effectively using the AMDS Hybrid Prosthesis.



October 5, 2023


LATE-BREAKING SCIENCE PRESENTED AT THE 37TH EUROPEAN ASSOCIATION FOR
CARDIO-THORACIC SURGERY ANNUAL MEETING



Artivion Announces Presentation of Real World Data from Post Market Study of
On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin



October 5, 2023


INTERIM DATA DEMONSTRATE MEANINGFUL REDUCTION OF ALL-CAUSE MORTALITY WITH AMDS



Artivion Announces Presentation of Late-Breaking Interim Data from AMDS
PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery
Annual Meeting



July 27, 2022


ARTIVION INITIATES ENROLLMENT IN PERSEVERE CLINICAL TRIAL



Study Designed to Evaluate the Safety and Efficacy of the AMDS Hybrid Prosthesis
to Treat Acute DeBakey Type I Aortic Dissections & Support U.S. FDA PMA
Submission.




FDA ACCEPTS CRYOLIFE IDE APPLICATION FOR PERSEVERE PIVOTAL IDE STUDY



A Prospective, Single Arm, Multi-center Clinical Investigation, to Evaluate the
Saftey and Effectiveness of AMDSTM  in the Treatment of Acute DeBakey Type I
Dissection



July 29, 2021


CRYOLIFE ANNOUNCES SALE OF PERCLOT TO BAXTER



CryoLife Announces the Sale of PerClot to a subsidiary of Baxter International,
Inc.



September 2, 2020


CRYOLIFE ACQUIRES ASCYRUS MEDICAL



CryoLife Acquires Ascyrus Medical LLC, Developer of AMDS Hybrid Prosthesis.
Ascyrus is a Florida-based, privately-held developer of the Ascyrus Medical
Dissection Stent (AMDS™), the world’s first aortic arch remodeling device used
for the treatment of acute Type A aortic dissections.



January 29, 2024


ARTIVION ANNOUNCES PRESENTATION OF LATE-BREAKING DATA FROM AMDS PERSEVERE TRIAL
AT THE 60TH SOCIETY OF THORACIC SURGERY ANNUAL MEETING



Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause
Mortality and Primary Major Adverse Events (MAEs) at 30 days with use of AMDS in
Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion



November 9, 2023


ARTIVION ANNOUNCES COMPLETION OF ENROLLMENT IN PERSEVERE TRIAL.



The PERSEVERE trial is a prospective, multicenter, non-randomized clinical trial
to determine if patients with acute DeBakey Type I aortic dissection can be
treated safely and effectively using the AMDS Hybrid Prosthesis.



October 5, 2023


LATE-BREAKING SCIENCE PRESENTED AT THE 37TH EUROPEAN ASSOCIATION FOR
CARDIO-THORACIC SURGERY ANNUAL MEETING



Artivion Announces Presentation of Real World Data from Post Market Study of
On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin



October 5, 2023


INTERIM DATA DEMONSTRATE MEANINGFUL REDUCTION OF ALL-CAUSE MORTALITY WITH AMDS



Artivion Announces Presentation of Late-Breaking Interim Data from AMDS
PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery
Annual Meeting



ba



WHEN THE NEED IS AORTIC,
THE SOLUTION IS ARTIVION

Our intentional focus on the aorta and collaboration with the world’s foremost
cardiac and vascular surgeons allow us to leverage our combined expertise in the
development of new, innovative, life-changing aortic-centric technologies.

NOTE: All products and indications are not available/approved in all markets.
Please contact your local Artivion representative for details.

HEART VALVE

SOLUTIONS


 * ON-X® AORTIC HEART VALVE
 * ON-X® MITRAL HEART VALVE
 * ON-X® ASCENDING AORTIC PROSTHESIS
 * CHORD-X® MITRAL CHORDAL REPLACEMENT PRODUCTS
 * CRYOVALVE® SG PULMONARY HUMAN HEART VALVE
 * CRYOVALVE® AORTIC ALLOGRAFT

ALLOGRAFTS

CARDIAC & VASCULAR


 * CRYOVALVE® SG PULMONARY HUMAN HEART VALVE
 * CRYOVALVE® AORTIC ALLOGRAFT
 * CRYOPATCH® SG PULMONARY PATCH
 * CRYOGRAFT® DESCENDING THORACIC AORTA
 * CRYOARTERY® AORTOILIAC ARTERY
 * CRYOARTERY® FEMORAL ARTERY
 * CRYOVEIN® SAPHENOUS VEIN
 * CRYOVEIN® FEMORAL VEIN
 * CRYOVEIN® PC PEDIATRIC CONDUIT
 * CRYOPATCH® AUTOLOGOUS PERICARDIUM

AORTIC ARCH

SOLUTIONS


 * AMDS™ HYBRID PROSTHESIS
 * E-VITA® OPEN NEO HYBRID STENT GRAFT SYSTEM
 * NEXUS® AORTIC ARCH STENT GRAFT SYSTEM
 * NEXUS DUO™ AORTIC ARCH STENT GRAFT SYSTEM

THORACOABDOMINAL

SOLUTIONS


 * Artivex™ THORACIC EXTENSION STENT GRAFT SYSTEM
 * E-NSIDE™ TAAA MULTIBRANCH STENT GRAFT SYSTEM
 * E-XTRA DESIGN ENGINEERING

ABDOMINAL AORTA

STENT GRAFTS


 * E-TEGRA™ STENT GRAFT SYSTEM
 * E-LIAC™ STENT GRAFT SYSTEM

PERIPHERAL AORTA

STENT GRAFTS


 * E-LIAC™ STENT GRAFT SYSTEM

SURGICAL SEALANT




 * BIOGLUE® SURGICAL ADHESIVE

ANCILLARY SOLUTIONS

CARDIAC & VASCULAR


 * PHOTOFIX® DECELLULARIZED BOVINE PERICARDIUM
 * CARBONAID® & CarbonMini® CO2 DIFFUSER
 * E-WIRE GUIDEWIRE
 * FLOWLINE BIPORE
 * E-XPAND STENT GRAFT BALLOON CATHETER
 * FLOWLINE BIPORE HEPARIN
 * FLOWNIT BIOSEAL
 * FLOWWEAVE BIOSEAL

E-XTRA DESIGN ENGINEERING




 * E-XTRA DESIGN ENGINEERING


PATIENT-POWERED PROGRESS

We provide solutions that have far-reaching impact on surgical outcomes and
restoring the lives of patients fighting aortic diseases. Cardiac and vascular
surgeons the world over—along with each patient in their care—have greatly
benefited from our life-changing technologies.

Click for sound





3:00










Click for sound



6:22










Click for sound



4:41











ADVANCING AORTIC TECHNOLOGIES WITH PURPOSE™

 * About
 * Products
 * Education

 * Donor Services
 * Quality & Safety
 * Investors
 * Careers

 * News
 * Events
 * Contact

 * 
 * 
 * 
 * 

©2024 Artivion, Inc
 * Privacy Policy
 * Terms of Use
 * EthicsPoint Compliance Reporting
 * Imprint


We use cookies on our website to give you the most relevant experience by
remembering your preferences and repeat visits. By clicking “Accept All”, you
consent to the use of ALL the cookies. However, you may visit "Cookie Settings"
to provide a controlled consent Read More.
Cookie SettingsAccept All
Manage consent
Close

PRIVACY OVERVIEW

This website uses cookies to improve your experience while you navigate through
the website. Out of these, the cookies that are categorized as necessary are
stored on your browser as they are essential for the working of basic
functionalities of the ...
Necessary
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly.
These cookies ensure basic functionalities and security features of the website,
anonymously.

CookieDurationDescriptioncookielawinfo-checkbox-analytics11 monthsThis cookie is
set by GDPR Cookie Consent plugin. The cookie is used to store the user consent
for the cookies in the category "Analytics".cookielawinfo-checkbox-functional11
monthsThe cookie is set by GDPR cookie consent to record the user consent for
the cookies in the category "Functional".cookielawinfo-checkbox-necessary11
monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to
store the user consent for the cookies in the category
"Necessary".cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR
Cookie Consent plugin. The cookie is used to store the user consent for the
cookies in the category "Other.cookielawinfo-checkbox-performance11 monthsThis
cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the
user consent for the cookies in the category
"Performance".viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie
Consent plugin and is used to store whether or not user has consented to the use
of cookies. It does not store any personal data.

Functional
Functional
Functional cookies help to perform certain functionalities like sharing the
content of the website on social media platforms, collect feedbacks, and other
third-party features.
Performance
Performance
Performance cookies are used to understand and analyze the key performance
indexes of the website which helps in delivering a better user experience for
the visitors.
Analytics
Analytics
Analytical cookies are used to understand how visitors interact with the
website. These cookies help provide information on metrics the number of
visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and
marketing campaigns. These cookies track visitors across websites and collect
information to provide customized ads.
Others
Others
Other uncategorized cookies are those that are being analyzed and have not been
classified into a category as yet.
SAVE & ACCEPT



 

 * Download BioGlue Surgical Adhesive Syringe eIFU (L6312.010)
 * Download BioGlue Surgical Adhesive Syringe eIFU (L6312.011)

 

 

x

 

 * Download BioGlue Surgical Adhesive Syringe eIFU (L6312.010)

 

 

x

 

 

Currently, there are no previous versions of this IFU.

 

 

x

 

 

 * Download BioGlue Patient Information Leaflet (L09331.000)

 

 

x

 

 

 * Download BioGlue Patient Implant Card (l09279.000)

 

 

x

 

 

Currently, there are no previous versions of this Patient Information Leaflet.

 

 

x

 

 * Download On-X Heart Valve System eIFU 010122 77 [E] (HV)
 * Download On-X Heart Valve System eIFU AUS-LBL00179 [C] (Instruments)
 * 

 

 

x

 

 * Download BioGlue Surgical Adhesive Syringe eIFU (L6312.011)

 

 

x

 

 * Download BioGlue Surgical Adhesive Syringe eIFU (L09418.000)

 

 

x

 

 

Currently, there are no previous versions of this Patient Information Leaflet.

 

 

x

 

 * Currently, there are no previous versions of this Patient Brochure.

 

 

x

 

 * Currently, there are no previous versions of this IFU.

 

 

x

 

 

Currently, there are no previous versions of this IFU.

 

 

x

 

 

Currently, there are no previous versions of this Patient Implant Card.

 

 

x

 

 

Currently, there are no previous versions of this Patient Information Leaflet.

 

 

x